 PHILADELPHIA, May 27, 2021 GLOBE NEWSWIRE -- Cabaletta Bio, Inc. Nasdaq: CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m. ET. 